Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The financial and real estate advisory firm announced its final results for the year ended 30 April 2026. Revenue rose 10% to £168.5m, driven by 8% organic growth.</li>
<li>Adjusted EBITDA increased 5% to £33.3m, while adjusted profit before tax rose 6% to £25.0m.</li>
<li>The group ended the year with net debt of £1.0m following acquisitions, dividends and share buybacks. </li>
</ul>


The financial and real estate advisory firm announced its final results for the year ended 30 April 2026. Revenue rose 10% to £168.5m, driven by 8% organic growth.
Adjusted EBITDA increased 5% to £33.3m, while adjusted profit before tax rose 6% to £25.0m.
The group ended the year with net debt of £1.0m following acquisitions, dividends and share buybacks. 


Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

<p>Following our note on BTG’s interim results, the proposed £3.3bn all-cash acquisition by Boston Scientific was announced. Further, on 21 November, BTG and its partner Johnson & Johnson (J&J) failed to prevent the launch of generic competition to Zytiga (28% of BTG’s H1 revenue). We examine the potential impact of generic Zytiga on the transaction.</p>

Following our note on BTG’s interim results, the proposed £3.3bn all-cash acquisition by Boston Scientific was announced. Further, on 21 November, BTG and its partner Johnson & Johnson (J&J) failed to prevent the launch of generic competition to Zytiga (28% of BTG’s H1 revenue). We examine the potential impact of generic Zytiga on the transaction.

BTG - The BTG acquisition: Small fly, big ointment

United Kingdom

BTG plc was an international specialist healthcare company that developed and commercialized products targeting critical care, cancer, and other disorders. Its portfolio included interventional medicine products for liver tumors, emphysema, blood clots, and varicose veins, alongside specialty pharmaceuticals. The company was headquartered in London, United Kingdom, and was founded in 1948 as the National Research Development Corporation, later becoming BTG in 1998.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BTG (BTG LN)

Hybridan Small Cap Feast: 6 July 2026

he financial and real estate advisory firm announced its final results for the year ended 30 April 2026. Revenue rose 10% to £168.5m, driven by 8%...

Hybridan

BTG - The BTG acquisition: Small fly, big ointment

Following our note on BTG’s interim results, the proposed £3.3bn all-cash acquisition by Boston Scientific was announced. Further, on 21 November,...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)